[go: up one dir, main page]

US2799660A - Blood test composition and method - Google Patents

Blood test composition and method Download PDF

Info

Publication number
US2799660A
US2799660A US423524A US42352454A US2799660A US 2799660 A US2799660 A US 2799660A US 423524 A US423524 A US 423524A US 42352454 A US42352454 A US 42352454A US 2799660 A US2799660 A US 2799660A
Authority
US
United States
Prior art keywords
tablet
blood
test
water
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US423524A
Inventor
Richard S Nicholls
Dale E Fonner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB11558/52A priority Critical patent/GB708996A/en
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Priority to US423524A priority patent/US2799660A/en
Priority to GB37258/54A priority patent/GB772374A/en
Priority to FR1119775D priority patent/FR1119775A/en
Priority to CH339401D priority patent/CH339401A/en
Priority to DEM26333A priority patent/DE1004398B/en
Application granted granted Critical
Publication of US2799660A publication Critical patent/US2799660A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • G01N33/725Haemoglobin using peroxidative activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/904Oxidation - reduction indicators

Definitions

  • This invention which relates to a diagnostic composition for detecting occult blood in animal fluids is a conatnt
  • the present invention is directed to a tablet which is 7,
  • the tablet of our invention is formed of a' mixture of a blood indicator such as, for example, o-a blood indicator
  • tolidine, o-toluidine, benzidine, o-tolidine-dihydrochloride and similar compounds an oxidizing agent of the peroxide type such as sodium carbonate peroxide, sodium perbor silicate, strontium peroxide, sodium pyrophosphate peroxide, barium peroxide, magnesium peroxide, and urea peroxide; an acetate such as calcium acetate, sodium acetate, potassium acetate, lithium acetate and the like; a water insoluble pigment or dye; and a water-soluble solid acid which is stronger than acetic acid so that it can react with the aforementioned acetate salt to produce acetic acid.
  • an oxidizing agent of the peroxide type such as sodium carbonate peroxide, sodium perbor silicate, strontium peroxide, sodium pyrophosphate peroxide, barium peroxide, magnesium peroxide, and urea peroxide
  • an acetate such as calcium acetate, sodium acetate, potassium acetate
  • Such acids are citric, fumaric, itaconic, maleic, rnalic, malonic, and mandelic acids.
  • an effervescent couple comprising, for example, an acid in solid dry form and a carbonate or bicarbonate which is preferably any alkaline earth or alkali metal carbonate or bicarbonate such as sodium, potassium, and calcium carbonates and bicarbonates. Diluents and excipients' of the kind conventionally used in preparation of tablets are likewise used in conjunction with the aforementioned materials.
  • the above composition is prepared in tablet form, each tablet containing conveniently 2 grains of material and being conveniently A; inch thick, and about A inch in diameter.
  • the composition contain, in addition to the blood indicator and an oxidizing agent, an acetate, a water soluble organic acid such as tartaric acid which is capable of releasing acetic acid when contacted with an acetate, and an effervescent couple. Without the co-presence of these materials neither the degree of sensitivity nor the degree of reproducibility of test results will be adequate.
  • Strontium peroxide From '5 to 15, preferably 9. Tartaric acid From 20 to 60, preferably 30. Calcium acetate From 20 to 75, preferably 60.
  • Corn starch From 1 to 10, preferably 5.
  • Effervescent couple From 5 to 20, preferably 10.
  • o-Tolidine From 0.5-4, preferably 1.
  • Stront um peroxide From 5-15 preferably 7.5.
  • Succ mc acid From 20-75, preferably 40.
  • Calcium acetate From 20-75, preferably 60.
  • Corn starch From 1-10, preferably 5.
  • Effervescent couple From 5-20, preferably 10.
  • o-Tolidine From 1-6, preferably 4.
  • Sodium perbor silicate From 8-20, preferably 10.
  • Succrnic acid From 20-75, preferably 40.
  • Calcium acetate From 20-75, preferably 60.
  • Corn starch From 1-10, preferably 5.
  • Effervescent couple From 5-20, preferably 10.
  • o-Tolidine From 0.5-4, preferably 1.
  • Strontium peroxide Itaconic acld Calcium acetate Corn starch Effervescent coup From 5-15, preferably 7.5. From 20-75, preferably 40. From 20-75, preferably 60. From 1-10, preferably 5.
  • Benzidine hydrochloride From Strontium peroxide 'lartaric acid 1-5, preferably 1. 5-15, preferably 7.5. 20-60, preferably 30.
  • Calcium acetate From 20-75, preferably 60.
  • Efiervescent couple From 5-20, preferably 10.
  • the present invention is particularly useful in the determination of occult blood in the presence of urine and, in sharp contrast with diagnostic compositions of the prior art, is sensitive to the extent of detecting of one part blod in 100,000 of uncentrifuged urine.
  • tablet A is of the general type of prior art compositions such as are described, for example, in U. S. Patent 2,290,436, that tablet B is the composition of tablet A to which calcium acetate has been added and that tablet 'C is of the same composition as tablet A to which both calcium acetate and efliervescent couple have been added.
  • Tablet D is the same composition as tablet C so modified as to include a water-insoluble pigment or dye.
  • a water-insoluble pigment or dye To incorporate the pigment or dye in the tablet it is simply necessary that it is dry and finely divided and it is then mixed intimately with the remainder of the composition prior to compressing the material into tablets.
  • the amount of pigment required would obviously vary depending on its hiding power and opacity, therefore the amount considered most satisfactory for any given pigment must be determined by trial. However, the necessary amount is generally not very much, being present
  • the superior performance of tablet B over tablet A shows that the addition of calcium acetate increases considerably'the sensitivity of the test. Further it is obvious that tablet C is more uniform in reaction time than tablet B and in addition the sensitivity of the tablet within a given time period is very substantially improved.
  • the tablets B and C were both compared by testing them with the sediments obtained by centrifuging samples of urine containing very small quantities of blood.
  • blood was diluted with normal urine to produce blood concentrations of 1 part in 50,000; 1 part in 100,- 000; 1 part in 300,000 and 1 part in 1,000,000 parts of urine.
  • 15 cc. of one of the specimens was centrifuged in a conical tube at moderate speed. The *the mannerdescribed can be illustrated by the following supernatant liquid was drawn off and the sediment which remained tested by placing 1 drop of it on filter paper and then proceeding with the test as previously described.
  • a Perthe added coloring material should be a water-insoluble Ohlde Whlhh h hberate hydrogeh. pehoxlde Water pigment or dye so that it will not leach away from the soluble .sohd.acld strohghr than achhc i ah acetate reagent material with which it is combined in the tablet Shh h whl rhact Wlth the last sand and to Produce when the whole mass is wetted as described in the test.
  • the coloring materials should have the strontium peroxide, 20 to 60 parts tartaric acid, 20 to property of good opacity and hiding power so that they parts calcium acetate, 1 to 10 parts corn starch, 5 to 20 shall stand out well in contrast to blue and further they parts of a solid effervescent couple, and a minor amount shall cover up any tendency of the material of the test of a water-insoluble material contrasting in color with itself to turn blue. 75 the color formed in combination with blood by said The advantage of coloring the tableted composition in o-tolidine.
  • composition-in tablet form comprisinglarmemberaofthe-group consisting-of o-tolidine, o--
  • o-tolidine consisting of o-tolidine, o-toluidine, benzidine and o-tolidine dihydrochloride, a peroxide which will liberatelhy: drogen peroxide, an acetate selected from the group;-
  • a method of determining occult blood in urine which comprises rwettingma portion of dry filter paper withaurine, placing-ontthe ..urine wetted portion of said paper, a tablet, composed of a mixture comprising by a water soluble acid stronger than acetic acid, and Ian 15 gh fIOm-abOI-It Parts of wmpound effervescent couple.
  • a diagnostic composition in tablet form f0'l' 'dfi' tecting blood in the presence of urine comprising by weight from 0.5 to 4 parts o-tolidine, 5 to parts of 75 parts of calcium acetate, 1 to 10 parts cornstarch, and 5 to parts of a solid eflervescent couple, said tablet effecting a color change on urine wetted filter paper when placed on'suchlpaper andthe 'tablet'conta-cted with a small amount of water.
  • A'diagnosti'c 'composition'in tablet form for detecting blood intliepresence of urine comprising 1 part of 'o-tolidine; 9parts of strontium peroxide, parts of tartaric acid, parts of calcium acetate, 5 parts of 'cornstarch, and 10'parts' of'a solid efiervescent couple, the 30 tablet efie'ctingea color change on urine-Wetted filter paper upon which said "tablet is placed, after a small amount of water is placed on said 'table't.
  • composition of claim 2 wherein the said water- 5 insoluble material is'selected from the group consisting of red pigments, yellow pigments, and orange pigments.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Description

BLOOD TEST COMPGSITIQN AND METHOD Richard S. Nicholls and Dale E. Fonner, Elkhart, Ind., assignors to Miles Laboratories, Inc, Ellrhart, Ind, a corporation of Indiana No Drawing. Application April 15, 1954, Serial No. 423,524
Claims. (Cl. 252-408) This invention which relates to a diagnostic composition for detecting occult blood in animal fluids is a conatnt The present invention is directed to a tablet which is 7,
adapted for use in determining occult blood in such materials as urine and the like or in fluids containing urine which tablet is superior to the tableted compositions now available in several important respects, namely, in that with the present tablet the time of reaction is much more I uniform for any given concentration of blood, and fuf- I thermore, the sensitivity of the tablet within a given time is substantially and unexpectedly greater.
Generally, the tablet of our invention is formed of a' mixture of a blood indicator such as, for example, o-
tolidine, o-toluidine, benzidine, o-tolidine-dihydrochloride and similar compounds; an oxidizing agent of the peroxide type such as sodium carbonate peroxide, sodium perbor silicate, strontium peroxide, sodium pyrophosphate peroxide, barium peroxide, magnesium peroxide, and urea peroxide; an acetate such as calcium acetate, sodium acetate, potassium acetate, lithium acetate and the like; a water insoluble pigment or dye; and a water-soluble solid acid which is stronger than acetic acid so that it can react with the aforementioned acetate salt to produce acetic acid. Examples of such acids are citric, fumaric, itaconic, maleic, rnalic, malonic, and mandelic acids. Additionally, there must be present an effervescent couple comprising, for example, an acid in solid dry form and a carbonate or bicarbonate which is preferably any alkaline earth or alkali metal carbonate or bicarbonate such as sodium, potassium, and calcium carbonates and bicarbonates. Diluents and excipients' of the kind conventionally used in preparation of tablets are likewise used in conjunction with the aforementioned materials.
The above composition is prepared in tablet form, each tablet containing conveniently 2 grains of material and being conveniently A; inch thick, and about A inch in diameter. In determining the presence or absence of occult blood in a sample of urine a drop of the urine specimen is placed on a piece of dry filter paper, and when the drop has soaked into the paper a tablet prepared as above described is placed in the center of the drop and then two drops of water added to the tablet. With a positive test a ring of color appears on the filter paper surrounding the tablet, the color ranging fiom a very faint to a very deep blue, depending upon the concentration of blood in the sample. The higher the blood concentration, the deeper the color, and vice versa. The afore- 2,799,660 Patented July 16, 1957 said method of determining occult blood is found superior to the methods taught by the prior art, not only in the degree of sensitivity reached but also in the greater extent of reproducibility.
In connection with the composition and method of the present invention, it is absolutely essential that the composition contain, in addition to the blood indicator and an oxidizing agent, an acetate, a water soluble organic acid such as tartaric acid which is capable of releasing acetic acid when contacted with an acetate, and an effervescent couple. Without the co-presence of these materials neither the degree of sensitivity nor the degree of reproducibility of test results will be adequate.
While the formulation of our diagnositic composition may be varied in accordance with the procedures known to those skilled in the art, suitable formulations are as follows:
Strontium peroxide From '5 to 15, preferably 9. Tartaric acid From 20 to 60, preferably 30. Calcium acetate From 20 to 75, preferably 60.
Corn starch From 1 to 10, preferably 5. Effervescent couple From 5 to 20, preferably 10.
EXAMPLE II Components of reagent mixture:
o-Tolidine From 0.5-4, preferably 1. Stront um peroxide From 5-15 preferably 7.5. Succ mc acid From 20-75, preferably 40. Calcium acetate From 20-75, preferably 60. Corn starch From 1-10, preferably 5. Effervescent couple From 5-20, preferably 10.
EXAMPLE HI Components of reagent mixture:
o-Tolidine From 1-6, preferably 4. Sodium perbor silicate From 8-20, preferably 10. Succrnic acid From 20-75, preferably 40. Calcium acetate From 20-75, preferably 60. Corn starch From 1-10, preferably 5. Effervescent couple From 5-20, preferably 10.
EXAMPLE IV Components of reagent mixture:
o-Tolidine From 0.5-4, preferably 1.
Strontium peroxide Itaconic acld Calcium acetate Corn starch Effervescent coup From 5-15, preferably 7.5. From 20-75, preferably 40. From 20-75, preferably 60. From 1-10, preferably 5.
. From 5-20, preferably 10.
EXAMPLE V Components of reagent mixture:
Benzidine hydrochloride From Strontium peroxide 'lartaric acid 1-5, preferably 1. 5-15, preferably 7.5. 20-60, preferably 30.
Calcium acetate From 20-75, preferably 60.
Corn starch From 1-10, preferably 5.
Efiervescent couple From 5-20, preferably 10.
EXAMPLE VI Components of reagent mixture:
o-Tolidine-dihydrochloride- From 1-5, preferably 1.
The present invention is particularly useful in the determination of occult blood in the presence of urine and, in sharp contrast with diagnostic compositions of the prior art, is sensitive to the extent of detecting of one part blod in 100,000 of uncentrifuged urine.
The net effect of the effervescent couple and the acetate components of our formulation is to increase substantially the sensitivity, reproducibility and the speed of the test procedure. This is illustrated by tests performed with the following four (4) compositions, each being prepared as a 2 grain tablet:
4 only in trace amounts sufficient to establish a color tint in the tablet. Thus for the water insoluble coloring material D and C Red No. 35 it has been found that approximately one part in 1,000 parts of the remaining Tablet A 5 composition is adequate. Other suitable colors are D parts by Weight and C Yellow No. l1 and D and C Orange No. 17. HowoJIofidi 1 v r, almost any insoluble pigment or dye which con- Strontium peroxide 9 trasts strongly with blue would be satisfactory unless it Tartaric acid 30 sho ld In some other way interfere with the test as by Starch 5 10 reacting with another ingredient of the tablet. It is to Talcum 5 the general formulations of Examples I to VII above as 7 represented by tablets C and D that this application is Tablet B related, the peculiar merits of such formulations being Parts by welght made especially evident by comparison with the perf 1 formance of the other compositions of tablets A and B. strontium .Peroxlde 9 These tablets were tested as follows: 'f 30 Blood was diluted with normal urine to prepare sam- Calcmm acetate ples which contained blood in concentrations of 1:100,000, starch 5 l:20,000, and 1:40,000 parts of urine. To make the Talcum 5 test one drop of the specimen was placed on a filter aper T bl t C square laid out on a white tile. When the drop had Pa t by weight soaked into the paper a tablet was placed in the center o-Tolidine 1 of the wetted area and then two drops of Water added Strontium peroxide 9 so that they fell on the tablet and ran over onto the Tartari acid 30 paper. The examination of the test was made at the Calcium acetate 60 end of 2, 3, 4 and 5 minutes, the time being determined Starch 5 by a stop watch. Talcum 5 Each type table was tested a large number of times Efiervescent couple (tartaric acid and sodium biwith each of the 3 concentrations of blood. The results carbonate) 10 are recorded in Table I.
TABLE I Tablet A Tablet B Tablet 0 Concentration of blood added to urine Percent positive in Percent positive in Percent positive in No. No. No. Tests Tests Tests 2 3 4 a 2 3 4 5 2 3 4 5 min. min. min. min. min. min. min. min. min. min. min. min.
Tablet D Parts by weight o-Tolidine 1 Strontium peroxide 9 Tartaric acid 30 Calcium acetate Starch 5 Talcum 5 Effervescent couple 10 Water-insoluble pigment or dye 0.1
It will be noticed that tablet A is of the general type of prior art compositions such as are described, for example, in U. S. Patent 2,290,436, that tablet B is the composition of tablet A to which calcium acetate has been added and that tablet 'C is of the same composition as tablet A to which both calcium acetate and efliervescent couple have been added.
Tablet D is the same composition as tablet C so modified as to include a water-insoluble pigment or dye. To incorporate the pigment or dye in the tablet it is simply necessary that it is dry and finely divided and it is then mixed intimately with the remainder of the composition prior to compressing the material into tablets. The amount of pigment required would obviously vary depending on its hiding power and opacity, therefore the amount considered most satisfactory for any given pigment must be determined by trial. However, the necessary amount is generally not very much, being present The superior performance of tablet B over tablet A shows that the addition of calcium acetate increases considerably'the sensitivity of the test. Further it is obvious that tablet C is more uniform in reaction time than tablet B and in addition the sensitivity of the tablet within a given time period is very substantially improved.
In the practice of our invention we have found that our test procedure which employs filter paper provides a much more sensitive test than other methods such as placing a drop of the sample directly on the tablet or dissolving the reagent mixture in water and adding it to the specimen. Under these latter conditions tablet A gives a negative test for blood at 1:0,000 and indeed only a very slowly formed positive with 1 part of blood in 1,000 parts of urine. The sensitivity of any of the compositions to blood dissolved in water is much higher than it is to blood in urine. Urine appears to contain a factor which inhibits the formation of color with o-tolidine, benzidine, etc., in the presence of blood and a peroxide. The use of the filter paper seems to a large extent to get around this difliculty and brings about a marked increase in sensitivity.
The tablets B and C were both compared by testing them with the sediments obtained by centrifuging samples of urine containing very small quantities of blood. In this case blood was diluted with normal urine to produce blood concentrations of 1 part in 50,000; 1 part in 100,- 000; 1 part in 300,000 and 1 part in 1,000,000 parts of urine. In making the test 15 cc. of one of the specimens was centrifuged in a conical tube at moderate speed. The *the mannerdescribed can be illustrated by the following supernatant liquid was drawn off and the sediment which remained tested by placing 1 drop of it on filter paper and then proceeding with the test as previously described.
record. j V
A number of urines wereobtained which were judged by microscopic examination of the sediment to contain The results of a series of tests are recorded in the follow- 5 no red blood cells, and could thereforebe expected to. ing table. give negative tests, that is there should be no blue color- TABLE II [Tests on sediment after centrifuging] Tablet B Tablet Concentration of blood added to Percent positive in Percent positive inunne No. No.
Tests 2 3 4 5 Tests 2 8 4 5 min. min. min. min. min. min. min. min.
It is again seen from the above results that with tablet ng on the P p Surrounding the tablet material- A C positive readings were obtained more consistently and Series f SW carried Out in Which a number of reliably than when tablet B was used. operators tested the two tablet compositions witheach Notwithstanding the very meritorious results obtained 0f the mines but in Such a manner that y did not by the use f t bl t C as d ib d b there i some run the tests with the two tablets concurrently and so were slight diificulty in deciding whether the test employing unable to compare their findings with one composition tablet C reads positive or negative when there is extremely against their findings With another on the Same urine little or no blood in the test sample. In these situations P Altogether 600 tests were carried out with each the subjective viewpoint of the person reading the result eempeslheh, the readings being taken at theme of 2 has considerable effect since he is not guided by any clearly mlhuteswith tablet C, the testshh these negative mines d fi d 1 h were considered to show at least. a faintly positive test When using such a tablet as represented by tablet C m 7 cases 125% of h tests run, he in h in the manner described above, the test is considered to 35 .Senes of teste Performed Wlth T eempeslheh e be positive when blue color appears on the paper surmg a red Plgment, tablet m the manner desenbed rounding the reacting tablet. However, it is a fact that above q 9 taste or 15% of the total e eonsldered as the effervescent tablet reacts, the material of the as jhowmg anythmg but a clear negahve test; tablet sloughs oif onto the paper in the area immediately lhe tablet of the Present mventlon thus Provides an around the tablet. In places where the amount on the 40 lmhmved mhans for detechng fields Such as paper is relatively little it is sometimes difficult to decide h by which Ihhhhs vhthal ehhhhahoh of false whether the paper should be considered as having turned poslhve readings 1S achleved 1h h dhhchhy detectable blue or whether the blue color which can be seen is areas of ehremely. 10W cohcehtrahoh complete h some spilled over tablet material since there is a tendsehce h hh Wlth reshlhhg marked Improvement ency for the test material to take on a little gray or very test rehhhhlty pale blue color. Further than this, even when there is Havlhg thus described 9 lhvhhhoh 9 no question as to which is material and which is clear A hloohfdetechhg dlhghoshc composmoh m tablet paper there can be confusion from the shadows which form. hhhpnslhg a.c.ompohhd hh h the group the tablet throws on the paper because these often have h i of h ohohhdihe hehzldlhe h a light grayish cast and are irregular in outline since the tohdme dlhydrohhlonde a peroxlde which liberate tablet on efiervescing has lost its usual outline. hydrogehherohlde a Water Soluble .so'hd .ahld Stmhger We have found that these diiliculties can be eliminated than ahehc h acetate salt whlch react Wlth and the use of the test very greatly improved by the dethe Sald Sohd held to phohhce achhc h ah ehhervhh vice of coloring the material of the test tablet with a h and a Watehlhsolhhle hihterhh cohtrashhg coloring material which contrasts with the blue color of In Color h the color formed by sald color responslve a positive test in such a way that the contrasting color compouhh In Presehcehf i remains with the reagent material and does not diffuse A dlaghoshc composlhoh h tablet fohhhomphslhg out on its own into the paper and so hide the appearance ahlember h the group hh of h of a possible positive reaction. To achieve these objects h behzhhhe h .o'hhuhhhe dlhydrochlohhe a Perthe added coloring material should be a water-insoluble Ohlde Whlhh h hberate hydrogeh. pehoxlde Water pigment or dye so that it will not leach away from the soluble .sohd.acld strohghr than achhc i ah acetate reagent material with which it is combined in the tablet Shh h whl rhact Wlth the last sand and to Produce when the whole mass is wetted as described in the test. held ah ehervhsceht h and a water'soluble In addition, in order that the coloring material should perh h cohtrashhg m color Wlth the 00101 formed form its function of defining clearly where the reagent m combmatloh Wlth bleed by the Selected member of material is at the completion of the test, it is important Sald groupthat its color contrast strongly with the blue color which A diagnostic composition in a l t form for deforms on the paper when the test is positive and for this tecting blood in the presence of urine comprising by reason yellow, orange or red pigments are the most satisg from t0 4 P3115 O'tOIidhIle, 5 to 15 P511rts factory. Further, the coloring materials should have the strontium peroxide, 20 to 60 parts tartaric acid, 20 to property of good opacity and hiding power so that they parts calcium acetate, 1 to 10 parts corn starch, 5 to 20 shall stand out well in contrast to blue and further they parts of a solid effervescent couple, and a minor amount shall cover up any tendency of the material of the test of a water-insoluble material contrasting in color with itself to turn blue. 75 the color formed in combination with blood by said The advantage of coloring the tableted composition in o-tolidine.
8.--A diagnostic. composition-in tablet form comprisinglarmemberaofthe-group consisting-of o-tolidine, o--
toluidine. benzidine, o-tolidine ldihydrochloride, a, peroxidefor liberating hydrogen peroxide, alwater soluble 5 solidjacid stronger. than acetic acid and an effervescent couple, an acetic" sa'lt'which will react with the said solid acid to produce acetic acid, said tablet efiecting a color change on urine Wetted filter paper when placed thereon, and said tablet is contacted with asmall amount of form comprising a compound selected from thettgroupJfl W enwhen Said urine containslblood.
consisting of o-tolidine, o-toluidine, benzidine and o-tolidine dihydrochloride, a peroxide which will liberatelhy: drogen peroxide, an acetate selected from the group;-
consisting of calcium acetate and alkali metal acetates 9. A method of determining occult blood in urine which comprises rwettingma portion of dry filter paper withaurine, placing-ontthe ..urine wetted portion of said paper, a tablet, composed of a mixture comprising by a water soluble acid stronger than acetic acid, and Ian 15 gh fIOm-abOI-It Parts of wmpound effervescent couple.
6. A diagnostic composition in tablet form f0'l' 'dfi' tecting blood in the presence of urine comprising by weight from 0.5 to 4 parts o-tolidine, 5 to parts of 75 parts of calcium acetate, 1 to 10 parts cornstarch, and 5 to parts of a solid eflervescent couple, said tablet effecting a color change on urine wetted filter paper when placed on'suchlpaper andthe 'tablet'conta-cted with a small amount of water.
7. A'diagnosti'c 'composition'in tablet form for detecting blood intliepresence of urine comprising 1 part of 'o-tolidine; 9parts of strontium peroxide, parts of tartaric acid, parts of calcium acetate, 5 parts of 'cornstarch, and 10'parts' of'a solid efiervescent couple, the 30 tablet efie'ctingea color change on urine-Wetted filter paper upon which said "tablet is placed, after a small amount of water is placed on said 'table't.
lected from the-ugroup'consistingof o-tolidine, o-toluidine; benzidine' and o-tolidine dihydro-chloride; a peroxidezwhich liberates hydrogen peroxide, an acetate se-- lected from the group consisting of calcium acetate and strontium peroxide, 20 to 60 parts of tartaric acid, 20 to 20 alkali metal acetates, about 20 to Parts by Weight a water solublesolid acid stronger than acetic acid, and' about 5 to 20 parts of an eifervescentcouple and then adding'a small amount of water to said tablet.
10. The composition of claim 2 wherein the said water- 5 insoluble material is'selected from the group consisting of red pigments, yellow pigments, and orange pigments.
Kamlet July 21, 1942 Compton et al Oct. 23, 1945 UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 2,799,660 July 16, 1957 Richard S, Nicholle et 81.
It is hereby certified that error appears in the printed specification of the above numbered patent requiring correction and that the said Let oers Patent should read as corrected below.
Column 6, line 60, before "water" insert a line 63, after "acetic" strike out the comma; same line, for "water-soluble" read water-insoluble column 8 line 6, for "acetic" read acetate Signed and sealed this 8th day of October 1957.
(SEAL) Attest:
KARL H. AXLI NE ROBERT C. WATSON Attesting Oi'ficr Comnissioner of Patents

Claims (1)

  1. 2. A DIAGNOSTIC COMPOSITION IN TABLET FORM COMPRISING A MEMBER OF THE GROUP CONSISTING OF O-TOLIDINE, O-TOLUIOXIDE WHICH WILL LIBERATE HYDROGEN PEROXIDE, WATER DINE, BENZIDINE AND O-TOLUIDINE DIHYDROCHLORIDE, A PERSOLUBLE SOLID ACID STRONGER THAN ACETIC ACID AN ACETATE SALT WHICH WILL REACT WITH THE LAST SAID ACID TO PRODUCE ACETIC, ACID, AN EFFERVESCENT COUPLE, AND A WATER-SOLUBLE MATERIAL CONTRASTING IN COLOR WITH THE COLOR FORMED IN COMBINATION WITH BLOOD BY THE SELECTED MEMBER OF SAID GROUP.
US423524A 1954-04-15 1954-04-15 Blood test composition and method Expired - Lifetime US2799660A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB11558/52A GB708996A (en) 1954-04-15 1952-05-07 Improvements in or relating to diagnostic compositions
US423524A US2799660A (en) 1954-04-15 1954-04-15 Blood test composition and method
GB37258/54A GB772374A (en) 1954-04-15 1954-12-23 Blood test
FR1119775D FR1119775A (en) 1954-04-15 1955-01-11 Diagnostic composition
CH339401D CH339401A (en) 1954-04-15 1955-01-14 Reagent for the detection of blood for diagnostic purposes
DEM26333A DE1004398B (en) 1954-04-15 1955-03-05 Diagnostic preparation in tablet form for the detection of blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US423524A US2799660A (en) 1954-04-15 1954-04-15 Blood test composition and method

Publications (1)

Publication Number Publication Date
US2799660A true US2799660A (en) 1957-07-16

Family

ID=23679205

Family Applications (1)

Application Number Title Priority Date Filing Date
US423524A Expired - Lifetime US2799660A (en) 1954-04-15 1954-04-15 Blood test composition and method

Country Status (5)

Country Link
US (1) US2799660A (en)
CH (1) CH339401A (en)
DE (1) DE1004398B (en)
FR (1) FR1119775A (en)
GB (2) GB708996A (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2905594A (en) * 1956-04-25 1959-09-22 Herman J Morris Means for detecting enzyme activity
US2970945A (en) * 1958-10-03 1961-02-07 Miles Lab Diagnostic composition
US3068855A (en) * 1957-04-29 1962-12-18 Jr Norman B Furlong Disposable blood-gas analyzer
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic
US3335793A (en) * 1964-11-30 1967-08-15 Cities Service Oil Co Method and composition for improving and maintaining the capacity of water injection wells
US3411887A (en) * 1964-06-15 1968-11-19 Miles Lab Diagnostic composition
USRE28575E (en) * 1971-03-01 1975-10-21 Indicator for detecting hydrogen peroxide and peroxidative compounds containing alpha naphthoflavone
US4148611A (en) * 1978-06-28 1979-04-10 Miles Laboratories, Inc. Test composition, device and method for the detection of peroxidatively active substances
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
US4394452A (en) * 1977-05-31 1983-07-19 Rohm Gmbh Synthetic stool
EP0177244A3 (en) * 1984-09-26 1986-12-17 Warner-Lambert Company A method for the detection of peroxidase activity
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
EP0227602A3 (en) * 1985-12-20 1988-04-06 Warner-Lambert Company Free flowing granular indicator material for peroxidase-like activity
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US6046019A (en) * 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
US6225123B1 (en) * 1997-04-30 2001-05-01 Becton Dickinson And Company Additive preparation and method of use thereof
US6534016B1 (en) 1997-04-30 2003-03-18 Richmond Cohen Additive preparation and method of use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164534A (en) * 1954-04-13 1965-01-05 Miles Lab Diagnostic composition
US2981606A (en) * 1955-06-20 1961-04-25 Lilly Co Eli Glucose indicator and method
US2848308A (en) * 1955-12-05 1958-08-19 Miles Lab Composition of matter
IT568716A (en) * 1956-02-03
IT569423A (en) * 1956-04-12
JP3003152B2 (en) * 1990-03-20 2000-01-24 吉富製薬株式会社 Method for measuring free hemoglobin and reagent kit for measuring free hemoglobin used therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2290436A (en) * 1940-09-26 1942-07-21 Miles Lab Diagnostic composition and method
US2387244A (en) * 1942-06-19 1945-10-23 Miles Lab Tablet and method of dissolving same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2290436A (en) * 1940-09-26 1942-07-21 Miles Lab Diagnostic composition and method
US2387244A (en) * 1942-06-19 1945-10-23 Miles Lab Tablet and method of dissolving same

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2905594A (en) * 1956-04-25 1959-09-22 Herman J Morris Means for detecting enzyme activity
US3068855A (en) * 1957-04-29 1962-12-18 Jr Norman B Furlong Disposable blood-gas analyzer
US2970945A (en) * 1958-10-03 1961-02-07 Miles Lab Diagnostic composition
DE1265453B (en) * 1961-05-04 1968-04-04 Miles Lab Diagnostic agent intended for the detection of blood
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic
US3411887A (en) * 1964-06-15 1968-11-19 Miles Lab Diagnostic composition
US3335793A (en) * 1964-11-30 1967-08-15 Cities Service Oil Co Method and composition for improving and maintaining the capacity of water injection wells
USRE28575E (en) * 1971-03-01 1975-10-21 Indicator for detecting hydrogen peroxide and peroxidative compounds containing alpha naphthoflavone
US4394452A (en) * 1977-05-31 1983-07-19 Rohm Gmbh Synthetic stool
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
US4148611A (en) * 1978-06-28 1979-04-10 Miles Laboratories, Inc. Test composition, device and method for the detection of peroxidatively active substances
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
EP0177244A3 (en) * 1984-09-26 1986-12-17 Warner-Lambert Company A method for the detection of peroxidase activity
EP0227602A3 (en) * 1985-12-20 1988-04-06 Warner-Lambert Company Free flowing granular indicator material for peroxidase-like activity
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US6046019A (en) * 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
US6225123B1 (en) * 1997-04-30 2001-05-01 Becton Dickinson And Company Additive preparation and method of use thereof
US6534016B1 (en) 1997-04-30 2003-03-18 Richmond Cohen Additive preparation and method of use thereof
EP0875756B1 (en) * 1997-04-30 2004-02-18 Becton, Dickinson and Company Additive preparation and method of use thereof
KR100473726B1 (en) * 1997-04-30 2005-07-18 벡톤 디킨슨 앤드 컴퍼니 Additives and how to use them

Also Published As

Publication number Publication date
CH339401A (en) 1959-06-30
GB772374A (en) 1957-04-10
DE1004398B (en) 1957-03-14
FR1119775A (en) 1956-06-25
GB708996A (en) 1954-05-12

Similar Documents

Publication Publication Date Title
US2799660A (en) Blood test composition and method
US3814668A (en) Method and device for the semi-quantitative determination of glucose in aqueous fluids
Udenfriend et al. Fluorescence characteristics of 5-hydroxytryptamine (serotonin)
US2848308A (en) Composition of matter
US4673654A (en) Composition for determining peroxidase-like activity of hemoglobin
US5055407A (en) Composition and method of assaying aqueous liquids for specific gravity
CN106198527A (en) A kind of ascorbic acid interference multi-term urine analysis test paper
US3123443A (en) Composition for diagnosing glucose
US5350694A (en) Composition method and device for measuring the divalent cation concentration or specific gravity of a test sample
US3654180A (en) Indicator for detecting hydrogen peroxide and peroxidative compounds containing alpha naphthoflavone
CA1260371A (en) Free flowing granular indicator material for peroxidase-like activity
US3016292A (en) Diagnostic composition
US3104209A (en) Composition for determination of glucose
US3042496A (en) Diagnostic composition
US4956300A (en) Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
EP0093595B1 (en) Home diagnostic aid and method for determining the presence of occult blood
EP0491936B1 (en) Very rapid detection of fungal infections
DE3851304T2 (en) Method and test composition for the determination of enzyme activity.
US3278394A (en) Method and composition for diagnosing glucose
EP0646795A1 (en) Reagent composition and method for determining lithium
CA2081870A1 (en) Detection of analytes in saliva using peroxide-peroxidase test systems
JP2522970B2 (en) Test piece for determination of creatinine in body fluid and method for producing the same
CA2920471C (en) A chlorine analytical test element and a stabilized n,n-diethyl-p-phenylenediamine solution
CA1254115A (en) Nonenzymatic glucose test
RU2260789C1 (en) Defectoscopic material set for capillary inspection